Respiratory Failure
Conditions
Brief summary
The aim of the study is to assess, in patients with acute hypoxemic respiratory failure, the short term physiologic effects of the high flow oxygen nasal therapy (Optiflow), in term of inspiratory muscle effort, gas exchange, comfort and dyspnea
Detailed description
The administration of a known concentration of oxygen is an important part of routine care of the patient admitted in intensive care unit for acute hypoxemic respiratory failure. A new high flow oxygen delivery system (Fisher and Paykel Health care) has been developed (Optiflow). The system used a heated humidifier and heated breathing circuit via a nasal interface. High flow nasal therapy (Optiflow) is associated with the generation of significant positive airway pressure in healthy volunteers. Positive expiratory pressure may have a number of benefits in respiratory failure which include improved ventilation/perfusion matching with improved oxygenation, reduced airways resistance and reduced work of breathing. Moreover high flow nasal therapy may improve oxygen administration by decreasing oxygen dilution, decreasing death space and using high levels of humidification
Interventions
PROCEDUREO2stand
Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
PROCEDURECPAP
o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher & Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
PROCEDUREOptiflow
High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 \> 90%
Sponsors
University Hospital, Bordeaux
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Acute respiratory insufficiency, defined as the PaO2/FIO2 ratio of 300 mm Hg or less after breathing oxygen * The presence of lung infiltrates on a posteroanterior chest radiograph
Exclusion criteria
* Face or cranial trauma or surgery * Patients younger than 18 years * History of COPD * Acute respiratory acidosis (defined as a pH \<7.30 and a PaCO2 \>50 mm Hg) * Hemodynamic instability with arterial pressure \< 90mmHg * Respiratory instability with PaO2/FiO2\<100mmHg * ventricular arrhythmias * Excess respiratory secretions. * Upper gastrointestinal bleeding * Recent gastric or oesophageal surgery * Tracheostomy or other airways disorders * Pneumothorax * Contraindication of gastric probe insertion * Impossibility to insert the oesophageal probe
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inspiratory muscle effort : oesophageal pressure (Poes) and the oesophageal pressure time product (PTPoes) | Every 30 minutes for 90 minutes |
Secondary
| Measure | Time frame |
|---|---|
| Gas exchange :PaO2/FiO2 ratio | Every 30 minutes for 90 minutes |
| Comfort assessed using a five-item semi quantitative scale | Every 30 minutes for 90 minutes |
| Dyspnea assessed using a visual analogic scale | Every 30 minutes for 90 minutes |
Countries
France
Outcome results
None listed